Carregant...
Small Molecule Inhibitors of the PCSK9·LDLR Interaction
The protein–protein interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein receptor (LDLR) is a relatively new, and extremely important, validated therapeutic target for treatment and prevention of heart disease. Experts in the area agree that the first...
Guardat en:
| Publicat a: | J Am Chem Soc |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6404525/ https://ncbi.nlm.nih.gov/pubmed/29378408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jacs.7b09360 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|